PDCD1 and neoplasm: CDK4/6 inhibitors (e.g., Abemaciclib) enhance immunogenicity by increasing MHC-I and tumor antigen expression while suppressing regulatory T cell (Treg) proliferation, resulting in a higher CD8+/Treg ratio and improved synergy with PD-1 blockade, ultimately extending survival (25).